Premium
A Comparison of A 4% Modified Fluid Gelatin and A 6% Hydroxyethyl Starch on Haemodilution, Colloid Osmotic Pressure, Haemostasis and Renal Parameters in Healthy Ponies
Author(s) -
Gratwick Z.,
Viljoen A.,
Page P.C.,
Goddard A.,
Fosgate G.T.,
Lyle C.H.
Publication year - 2015
Publication title -
equine veterinary journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.82
H-Index - 87
eISSN - 2042-3306
pISSN - 0425-1644
DOI - 10.1111/evj.12486_42
Subject(s) - hydroxyethyl starch , hetastarch , partial thromboplastin time , creatinine , prothrombin time , thromboelastography , medicine , urine specific gravity , oncotic pressure , crossover study , fibrinogen , renal function , urology , urine , platelet , anesthesia , albumin , placebo , alternative medicine , pathology
Reasons for performing study Adverse effects on renal health and haemostasis have been documented in human patients administered hydroxyethyl starches ( HES ). Gelatins could provide useful substitutes for HES should similar adverse effects be identified in horses. Objectives To compare the effects of a 4% modified fluid gelatin ( MFG ) with a 130/0.4 6% tetrastarch ( TES ) on haemodilution, colloid osmotic pressure ( COP ), haemostasis and renal parameters in healthy ponies. Study design Randomised crossover. Methods Three treatments ( A = 10 ml/kg bwt TES , B = 10 ml/kg bwt MFG and C = 20 ml/kg bwt MFG ) were administered to 6 healthy ponies with a one‐week washout period. Packed cell volume ( PCV ), total serum protein ( TSP ), COP , platelet count, fibrinogen, prothrombin time ( PT ), activated partial thromboplastin time (a PTT ) and thromboelastography ( TEG ) were measured at baseline and at multiple time points up to 24 h post infusion. Serum creatinine, urine specific gravity ( USG ), urine protein:creatinine ( UPC ), urine GGT :creatinine ( UGC ) and urine sediment examination ( USE ) were performed before and 24 h after each treatment, and one week after the final treatment. Results All treatments caused significant haemodilution and increases in COP with treatment C having a significantly greater effect on PCV than other treatments. The platelet count decreased with all treatments and was significantly lower for treatment C compared with treatment B . No significant differences were observed in any TEG parameter within or between treatments. No significant differences in PT , aPTT or fibrinogen were observed between treatments. Serum creatinine, UGC and UPC did not change significantly pre‐ and post study. USG and USE remained within normal limits. Conclusions 4% MFG could be considered as an alternative to 130/0.4 6% TES for volume expansion and oncotic support. Neither MFG nor TES were associated with clinically significant adverse effects on haemostasis or renal parameters. Ethical animal research: This research was approved by the University of Pretoria's Animal Ethics Committee. The animals used in the study were part of a research herd belonging to The University of Pretoria. Sources of funding: The Department of Companion Animal Clinical Studies, Faculty of Veterinary Science, University of Pretoria, The Abe Bailey Trust Fund, The S outh A frican Veterinary Foundation and The S outh A frican Equine Veterinary Association. Competing interests: None declared.